menu search

Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress

Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress
Early clinical data on RMC-6236 provided in support of RAS(ON) Inhibitor platform validation Additional data releases for RMC-6236 (RASMULTI) and RMC-6291 (KRASG12C) expected in 2023 RMC-9805 (KRASG12D) expected to begin clinical development in mid-2023 Growing pipeline of development-stage assets, including RMC-0708 (KRASQ61H), that target every major RAS cancer mutation hotspot Webcast today at 4:30 p.m. […] The post Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Resu... Read More
Posted: Feb 27 2023, 21:05
Author Name: forextv
Views: 101917

Search within

Pages Search Results: